(415) 483-2488
CSNK2A1 Foundation Logo

Understanding
Okur-Chung Neurodevelopmental Syndrome

a logo for the csnk2al foundation

Understanding
Okur-Chung Neurodevelopmental Syndrome

Francesca DeMartino

BOARD OF DIRECTOR

Francesca DeMartino

Senior Vice President, Chief Investor Relations Officer, Pfizer Inc.


Francesca has nearly 25+ years of combined experience in Investor Relations, Communications, and Corporate Finance. She has counseled more than 25 private and public healthcare companies and C-level executives. She most recently held the position of Senior Vice President, Head of Investor Relations at BD (Becton Dickinson) (NYSE: BDX). Prior to BD she was Vice President, Investor Relations at Medtronic plc (NYSE: MDT). During her tenure at Medtronic, she was also Vice President, Corporate Communications and Vice President, Global Communications for the Diabetes Group. Prior to joining Medtronic, Francesca held positions of increasing responsibility at Johnson & Johnson, OMRIX Biopharmaceuticals, Macrocure Ltd, GCI Group and The Ruth Group. 


Francesca began her career at Alex. Brown & Sons (now Deutsche Bank) as a Financial Analyst in the Health Care Investment Banking Group. Her accomplishments include: recognition by IR Magazine as "Best Overall Investor Relations" and "Best Investor Relations: Healthcare" in 2021.  While at OMRIX, she developed and led the IR function, which achieved "#1 Aftermarket Performance Among 2006 Healthcare IPO's" and "#2 Aftermarket Performance Among 2006 IPO's Across All Industries".  She was also part of the Senior Management Team that completed a secondary offering, sale, and integration of OMRIX into Johnson & Johnson. Additionally, Francesca built and led Macrocure's Investor Relations function through its Initial Public Offering, and its increased liquidity, broadened investor base, and returns of 40% from IPO. Lastly, she contributed to the Investor Relations program and $1.1B sale of Sirna Therapeutics to Merck & Co and she led Corporate Communications for Johnson & Johnson's $4B divestiture of Ortho-Clinical Diagnostics, which at the time was their largest divestiture to date. 


Ms. DeMartino is of Mexican and Italian descent and is a native Spanish and English speaker. She holds a B.A. in International and Area Studies from the University of California, Berkeley and a minor in Business Administration from the Walter A. Haas School of Business. She was also Visiting Student at Barnard College and Columbia University. Francesca, her husband David, and their English Bulldog, Sofia reside in New York City.

Share by: